MoonLake Immunotherapeutics MLTX
- sonelokimab — Hidradenitis Suppurativa NDA Submitted
- sonelokimab — Psoriatic Arthritis Phase 3
- sonelokimab — Palmoplantar Pustulosis Phase 2
- sonelokimab — Axial Spondyloarthritis Phase 2
IL-17F (3 companies · 9 programs)
Companies with an active program directed at IL-17F.
Oruka Therapeutics, Inc. ORKA
- ORKA-002 — Psoriasis Phase 2
- ORKA-002 — Psoriatic Arthritis
- ORKA-021 — Psoriasis
- ORKA-002 — Hidradenitis Suppurativa Phase 2
Protagonist Therapeutics, Inc PTGX
- PN-881 — Plaque Psoriasis Phase 1